How RXMD is going to get to $1 This is a 40x

New Post Public Reply Private Reply Replies (0) Message Board
MoneyForNuthin
How RXMD is going to get to $1

This is a 40x improvement over today's ~$0.025 share price. Do I think it will happen this year? Though some believe it's possible, I wouldn't bet the farm on it. Do I think it's very possible within the next 3-5 years? Absolutely! Here's how and why...

First, Progressive Care, Inc. (RXMD) is clearly undervalued, but the pps is correcting and will be reaching upward for 0.10+ before you know it. Organic growth and a handful of acquisitions - simply executing the strategic plan - will do the rest. I see RXMD as a serious buyout target in 2-3 years!

Large national pharmacy companies are fending off competition from mail-order prescription discounters, online pharmacies, wholesale retailers such as Costco and health clinics, among others:
[list]
[*]Dec 16, 2015 - CVS Health Corporation (NYSE:CVS) and Target Corporation (NYSE:TGT) announced today that CVS Health has completed the acquisition of Target's pharmacy and clinic businesses for approximately $1.9 billion.

[*]Oct 28, 2015 - Walgreens said on Tuesday that it will buy rival Rite Aid in a $17.2 billion deal that would whittle the nation's one-time mom-and-pop drug-store industry into two massive chains. Walgreens Boots Alliance, which operates the namesake drug store chain, said it is paying $9 per share in cash in a valuation that includes the assumption of debt. That reflects a 48% premium above Rite Aid's value at the close of trading Monday.

[*]Aug 19, 2015 - CVS Health Corp. (CVS - Analyst Report) has completed the acquisition of Ohio-based pharmacy services provider, Omnicare, for $12.7 billion, including a debt of $2.3 billion, well ahead of time. The buyout reflects the company’s foray into a new pharmacy distribution channel – the long-term specialty care market.

[*]From a 2010 article:
Omnicare has a rich history of growth through acquisitions, which has made it a dominant player in the industry. The company boasts a reasonably sound balance sheet and is well positioned with healthy cash flow, which it can use for further acquisitions, debt repayments and share repurchases. Omnicare is pursuing an aggressive acquisition strategy in fiscal 2010. The company agreed to buy institutional pharmacy businesses in July 2010 and is also in advanced negotiations for other acquisitions.[/list]
While the goliaths have been hammering away at acquisitions and consolidation in the broader pharmacy retail sales and services markets to maximize commodity-type margins, Progressive Care, Inc. (RXMD) has been quietly whittling away at a health services business model that focuses on a small but substantial piece of the very large pie. This piece of pie, however, concentrates on high-margin revenue derived from medications and services for an underserved segment of the market. Progressive Care specializes in the care and management of patients with special needs, long-term care needs, and including medications for infectious diseases.

As stated in the Open Letter to Shareholders, Progressive Care will continue to strengthen the successful PharmCo model by "adding business elements that cater to specific under-served markets and demographics." In doing so, Progressive Care raises the bar, creating a steeper barrier to entry for regional competition in existing markets. For example, Progressive Care will add a "closed-door pharmacy facility" to the existing PharmCo operation this year. It seems likely that this will be a nearby (near the existing PharmCo site) satellite pharmacy operation embedded in a long-term care or other health services facility in one of the underserved markets/demographics of focus.

As also stated in the Open Letter to Shareholders, Progressive Care "will also look for opportunities to expand the pharmacy through establishing new locations or through mergers/acquisitions with similarly positioned independent pharmacies," and "will seek licensures in additional states in order to begin positioning PharmCo as a national brand."

Progressive Care, Inc. (RXMD) has it in the game plan to grow revenue organically and to expand into other markets nationally through acquisitions.

The goliaths have it in their game plan to continue increasing shareholder value - indefinitely. As the pending market consolidation in the major pharmacy store and services sector is nearing completion, these companies will look to the next opportunities, especially those that offer higher gross margins. They will not be able to do this organically through existing infrastructure, as the services are much more specialized than what a discount pharmacy operation can profitably support. That is, it's simply not a good product mix. The only way they will be able to continue improving shareholder value at their historic rates is through acquisitions.

If you're trading on the OTCBB and you're new to RXMD, it would be a very smart move IMO to diversify your "investments" and take 10-20% of your funds and get a starting position in this stock for the long-haul growth toward this 40-50-60x gain opportunity over 3-5-7 years. Add when you can on any dips and stay long, and use other funds for flipping other penny stocks if that's something that appeals to you. Wanna retire young? This is a road map that's easy to read.

Compare Progressive Care to the average independent pharmacy
Scroll down for more posts ▼

Top 10 Most Recent News Articles

XKIG Bolsters Northwest with Jensen's Acquisition

Updated Category News Views 44

Stepping Up the Game in the Pacific Northwest Well, here we see another classic example of a shrewd move in the infrastructure sector. XKIG, a name known to those who keep an eye on critical infrastructure services for utilities, has decided to widen its footprint with a strategic grab of Jensen's Tree Service, Inc. They’re setting up shop even deeper in the Pacific...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
NVIDIA Faces Fraud Suit: Investors Called to Action

Updated Category News Views 85

NVIDIA and the Quest for Accountability Nothing screams chaos in the market louder than a securities fraud lawsuit hitting the headlines. Investors currently eyeballing NVIDIA Corporation (NASDAQ: NVDA) are in for a wild ride. Yep, you heard it right—NVIDIA is smack in the middle of a class action lawsuit. They're being accused of misleading the market about some shady...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 104

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 246

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 126

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading

Top 5 Most Recently Viewed Articles

Easterly ROCMuni Fund Investors: Understanding Your Rights

Updated Category News Views 110

Understanding the Easterly ROCMuni Fund Situation The Easterly ROCMuni High Income Municipal Bond Fund, formerly known as Principal Street High Income Municipal Fund, has recently come under scrutiny regarding its investment practices. Investors in the fund are encouraged to reach out to legal professionals to discuss potential claims related to significant financial...

Continue Reading
Is Bitcoin Ready for a Breakout Amid Bullish Sentiment?

Updated Category News Views 111

Bitcoin's Current Market Position Bitcoin (BTC/USD) is currently positioned near $115,000, just a day before significant decisions regarding interest rates by the Federal Reserve. Expectations are high, as many anticipate a rate cut of 25 basis points, which is igniting market discussions and predictions. Current Market Sentiment Recent data from Santiment highlights an...

Continue Reading
Nyxoah's Upcoming Presentation at Healthcare Conference Revealed

Updated Category News Views 168

Nyxoah to Present at Healthcare Conference Nyxoah SA, a leader in medical technology focused on treating Obstructive Sleep Apnea (OSA), is poised to showcase its advancements at an upcoming prominent event. The company will take part in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 4. This notable event is set to provide a platform for Nyxoah...

Continue Reading
Keros Therapeutics Welcomes Dr. Yung H. Chyung as CMO

Updated Category News Views 176

Keros Therapeutics Welcomes New Leadership Keros Therapeutics, Inc. (NASDAQ: KROS) is making waves with the recent appointment of Dr. Yung H. Chyung as their new Chief Medical Officer. This pivotal move signals the company's commitment to advancing its innovative drug development efforts, especially as they gear up for critical clinical milestones. Keros is known for its...

Continue Reading
Nestlé's Strategic Shake-Up: Leadership Changes and Impacts

Updated Category News Views 303

Unexpected Leadership Change at Nestlé In a surprising turn of events, Nestlé has dismissed its Chief Executive Officer, Laurent Freixe, due to his failure to communicate a romantic relationship with an employee who worked under his supervision. This decision highlights the strict adherence to corporate governance rules that Nestlé aims to uphold. Philipp Navratil...

Continue Reading